Showing 4101-4110 of 4164 results for "".
- TopiVert Announces First Patients Dosed in THEIA-1 Phase 2b/3 Study of Dry Eye Disease Treatmenthttps://modernod.com/news/topivert-announces-first-patients-dosed-in-theia-1-phase-2b-3-study-of-dry-eye-disease-treatment/2476259/TopiVert Pharma announced that the first patients have been dosed in the THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1 is a multicenter, randomised, double-masked, pl
- ReNeuron Group Announces Positive Preliminary Data in US Retinitis Pigmentosa Trialhttps://modernod.com/news/reneuron-group-announces-positive-preliminary-data-in-us-retinitis-pigmentosa-trial/2476276/ReNeuron Group announced positive preliminary results in the company’s ongoing phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2 part of the trial have demonstrate
- Registration Now Open for Neuro-Optometric Rehabilitation Association Meetinghttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-meeting/2476291/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 19-20) and 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona. The
- Topcon Healthcare Solutions and Oculo Form Global Partnershiphttps://modernod.com/news/topcon-healthcare-solutions-and-oculo-form-global-partnership/2476308/Topcon Healthcare Solutions (THS) and Oculo, a technology provider in clinical communications based out of Melbourne, Australia, have announced a new partnership that will combine the strengths of their Topcon Harmony and Oculo eye care platforms. Financial terms of the deal were not disc
- Bruder Announces Eyeleve Contact Lens Compresshttps://modernod.com/news/bruder-announces-eyeleve-contact-lens-compress/2479603/Bruder Healthcare announces the immediate availability of Eyeleve, a compress clinically proven to increase comfortable contact lens wear time by up to 3 hours daily. The Eyeleve Contact Lens Compress delivers consistent, therapeutic moist heat that alleviates symptoms of meibomian gland d
- Compulink Showcases SMART Ophthalmology EHR Solution at Hawaiian Eye 2019https://modernod.com/news/compulink-showcases-smart-ophthalmology-ehr-solution-at-hawaiian-eye-2019/2476177/Compulink Healthcare Solutions will demonstrate its ophthalmology-specific system, Ophthalmology Advantage at Hawaiian Eye. Ophthalmology Advantage uses AI technology and real-time data from the clinic to completely automate tasks such as billing, along with eliminating steps to improve pa
- Burnout Rises Above 50% in Some Specialties, New Survey Showshttps://modernod.com/news/burnout-rises-above-50-in-some-specialties-new-survey-shows/2476179/Responses to a new Medscape survey indicate that 44% of physicians meet the criteria for burnout, up from 42% in last year’s report. In addition, 11% are colloquially depressed (feeling down or sad), and 4% are clinically depressed, according to the
- Aerpio Pharmaceuticals Completes Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-completes-patient-dosing-in-time-2b-study-of-akb-9778-in-diabetic-retinopathy/2476181/Aerpio Pharmaceuticals announced the completion of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe nonproliferative diabetic retinopathy (NPDR). &#
- Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR Implant for Lowering IOPhttps://modernod.com/news/allergan-announces-positive-3-month-topline-results-from-second-phase-3-study-of-bimatoprost-sr-implant-for-lowering-iop/2476215/Allergan announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Positive results from the first phase 3 tri
- Ophthotech Announces the Addition of Calvin W. Roberts, MD, to Its Board of Directorshttps://modernod.com/news/ophthotech-announces-the-addition-of-ophthalmic-industry-leader-calvin-w-roberts-md-to-its-board-of-directors/2476231/Ophthotech Corporation announced the election of Calvin (Cal) W. Roberts, MD, Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies, and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, to its Board of Directors, effective as of Ja